The data we have comes from separate trial programs with different designs, different patient populations, and different endpoints
In one trial , participants lost about 2% of their body weight after the first month of taking semaglutide
On 7 April, the FDA published several warning letters, including a batch to companies that the agency said are marketing GLP-1 products, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) products, and triple agonist (GLP-1/GIP/glucagon) products without regulatory approval
it may progress to central hyperventilation, seizures, coma, and death if left untreated
We make weight loss accessible, transparent, and personalized with one flat fee no hidden costs, no subscriptions, and no surprise billing
This is called pulmonary aspiration, and it is serious